Abstract
Background A multitude of genetic variants confer a risk of Parkinson’s disease (PD), however, whether these risk variants affected the motor symptoms of PD patients remain largely elusive. The objective of this study is to investigate the effects of BCKDK rs14235 (G > A), a risk variant associated with PD risk, on the motor manifestations and brain networks of PD patients.
Methods PD patients (n = 146) receiving magnetic resonance imaging from Parkinson’s Progression Markers Initiative (PPMI) database were investigated. The effects of BCKDK rs14235 on the motor manifestations and brain networks of PD patients were systematically evaluated.
Results BCKDK rs14235 A allele was associated with milder motor symptoms in PD patients. BCKDK rs14235 significantly modified the topology of brain structural and functional network. The assortativity in structural network was negatively associated with rigidity in PD while the shortest path length of right pallidum was positively associated with Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) scores. The mediation analysis suggested that assortativity in structural network mediated the effects of BCKDK rs14235 on rigidity and the shortest path length of right pallidum mediated the effects of BCKDK rs14235 on UPDRS-III scores.
Conclusions BCKDK rs14235 significantly shaped the motor impairment and network topology of PD patients. Differential network metrics mediated the effects of BCKDK rs14235 on rigidity and UPDRS-III scores of PD patients. Future studies were required to identify the molecular mechanisms underlying the effects of BCKDK rs14235 on motor impairment and brain network metrics of PD patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PPMI study was approved by Institutional Review Board of each participating site. The informed consents were signed from all participants and could be obtained from the investigators of each participating site.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
